The Impacts of Decisions and Outcomes in - amazonia.fiocruz.br

The Impacts of Decisions and Outcomes in - was

What is this page? The authors hypothesized that a multiparameter intraoperative decision support system with real-time visualizations may improve processes of care and outcomes. The secondary outcome measures were myocardial injury, acute kidney injury, mortality, length of hospital stay, and encounter charges. A total of 26, patients were evaluated: 7, experimental cases, 10, parallel controls, and 7, historical controls. The secondary clinical outcome measures were not significantly affected. The use of an intraoperative decision support system was associated with improved process measures, but not postoperative clinical outcomes. This page is provided by Altmetric. Altmetric Badge. High Attention Score compared to outputs of the same age and source 98th percentile. Mentioned by news 9 news outlets policy 1 policy source twitter 26 tweeters facebook 4 Facebook pages. The Impacts of Decisions and Outcomes in

These considerations for mRNA vaccines only apply to the currently authorized vaccine products in the United States i. Impactw addition to the following considerations, the EUA conditions of use and storage, handling, and administration procedures described in the prescribing information should be referenced when using the Pfizer-BioNTech external icon and Moderna external icon COVID vaccines.

Navigation menu

Children and adolescents outside of these authorized age groups should not receive COVID vaccination at this time. Persons should not be scheduled to receive the second dose earlier than recommended i. However, second doses administered within a grace period of 4 days earlier than the recommended date for the second dose are still considered valid. Doses inadvertently administered earlier than the grace period should not be repeated. The second dose should be administered as close to the recommended interval as possible. However, if it is not feasible to adhere to the recommended interval, the second dose of Pfizer-BioNTech and Moderna COVID vaccines may be scheduled for administration up to 6 weeks 42 days after the first dose. If the second dose is administered beyond these intervals, there is no need to restart the series.

The safety and efficacy of a mixed-product series have not been evaluated. Both doses of the series should be completed with the same product. Strategies to help ensure that patients receive the second dose with the appropriate product and interval between doses include:. Using the above strategies, every effort should be made to determine which vaccine product was received as the first dose, in order to ensure completion of the vaccine series with the same product. If two doses of different mRNA COVID vaccine products are administered in these situations or inadvertentlyno additional doses of either product are recommended at this time.

Introduction

Recommendations may be updated as further information becomes available or other vaccine types e. Given the lack of data on the safety and efficacy of mRNA COVID vaccines administered simultaneously with other vaccines, the vaccine series should routinely be administered alone, with a minimum interval of 14 days before or after administration with any other vaccine. However, mRNA COVID and other vaccines may be administered within a shorter period in situations where the benefits of vaccination are deemed to outweigh the potential unknown risks of vaccine coadministration e.

No additional doses The Impacts of Decisions and Outcomes in the two-dose primary series are recommended at this time. Vaccination should be offered The Impacts of Decisions and Outcomes in persons regardless of history of prior symptomatic or asymptomatic SARS-CoV-2 infection. Viral testing to assess for acute SARS-CoV-2 infection or serologic testing to assess for prior infection for the purposes of vaccine decision-making is not recommended. Vaccination of persons with known current SARS-CoV-2 infection should be deferred until the person has recovered from the acute illness if the person had symptoms The Dark Of Knight Lighting criteria have been met for them to discontinue isolation.

Thus, while vaccine supply remains limitedpersons with recent documented acute SARS-CoV-2 infection may choose to temporarily delay vaccination, if desired, recognizing that the risk of reinfection, and therefore the need for vaccination, may increase with time following initial infection. For vaccinated persons who subsequently develop COVID, prior receipt of an mRNA COVID vaccine should not affect treatment decisions including use of monoclonal antibodies, convalescent plasma, antiviral treatment, or corticosteroid administration or timing of such treatments.

This recommendation applies to persons who receive passive antibody therapy before receiving any vaccine doses as well as those who receive passive antibody therapy after the first dose but before the second dose, in which case the second dose should be deferred for at least 90 days following receipt of the antibody therapy. Thus, there is no recommended minimum interval between other antibody therapies i. Thus, vaccination is unlikely to be effective in preventing disease following an exposure. In these settings, healthcare personnel are already in close contact with residents e.

Mentioned by

Vaccinators should employ appropriate infection prevention and control procedures. Residents of other congregate settings e. However, where feasible, precautions should be taken to limit mixing exposed individuals with other residents The Impacts of Decisions and Outcomes in staff except those essential for the provision of vaccination services, who should employ appropriate infection and control procedures.

Persons residing in congregate settings healthcare and non-healthcare who have had an exposure and are awaiting results of SARS-CoV-2 testing may be vaccinated if the person does not have symptoms consistent with COVID In situations where facility-wide testing is being conducted to identify SARS-CoV-2 infections, facilities should attempt to complete facility-wide testing within a period that allows for test results to be received prior to vaccination in order to isolate Deciisons patients with SARS-CoV-2 infection. However, it is not necessary to wait for test results if this would create delays in vaccination.

Although not contraindicated, vaccination may be deferred pending outcome of testing in persons with symptoms consistent with COVID Clinical trials demonstrated similar safety and efficacy profiles in persons with some underlying medical conditions, including those that place them at increased risk for severe EDcisionscompared to persons without comorbidities. Information on groups with specific underlying medical conditions is included below. Persons with HIV infection or other immunocompromising conditions, or who take immunosuppressive medications or therapies might be at increased risk for severe COVID Data are not currently available to establish vaccine safety and efficacy in these groups. Immunocompromised individuals may receive COVID vaccination if they have no contraindications to vaccination.]